In Rare Diseases and Orphan Drugs journal, there is a new publication named: “Pre-transfusion screening and thalassemia – why, what, and how?”
The article, written by Yonka Lazarova et al., examines the importance and specifics of pre-transfusion screening in thalassemia. It presents how the quality of life for individuals with transfusion-dependent thalassemia is largely determined by the safety and effectiveness of transfusion therapy. The authors emphasize the role of pre-transfusion screening for anti-erythrocyte antibodies as a key tool for preventing alloimmunization and avoiding adverse reactions or complications following blood transfusion.
The text discusses that anti-erythrocyte antibodies of clinical significance can lead both to hemolytic disease of the fetus and newborn (HDFN) and to ineffective blood transfusions. Genotyping is highlighted as an essential step in prenatal medicine and for alloimmunized patients with multiple specificities, for assessing the risk of HDFN and ensuring safe transfusion therapy. It is stressed that good transfusion management in thalassemia is associated with prolonged survival of allogeneic erythrocytes and the absence of complications from polytransfusion therapy.
You can read the full article here: https://journal.raredis.org/index.php/RBLS/article/view/232